文献速递其他结缔组织病类风湿关节炎脊柱关节炎

癌症合并自身免疫病患者使用免疫检查点抑制剂的安全性与疗效:全国多中心队列研究

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
PubMed 文献 · Arthritis Rheumatol · 2019-10-21

该回顾性队列研究纳入112例合并自身免疫病的癌症患者,评估免疫检查点抑制剂(ICI)的安全性与疗效。中位随访8个月,71%出现自身免疫病 flare 和/或其他免疫相关不良事件(IRAE),多数可管理。基线使用免疫抑制治疗者中位无进展生存期较短(3.8个月 vs 12个月,P=0.006)。

要点

  • 合并自身免疫病的癌症患者使用ICI时,flare或IRAE发生率高(71%),但多数无需停药。
  • 基线免疫抑制治疗与较短的中位无进展生存期相关(3.8个月 vs 12个月,P=0.006)。
  • 出现flare或IRAE者中位无进展生存期较短,未用免疫抑制剂或未停ICI者生存趋势更好。

核心结论

  • 合并自身免疫病的癌症患者使用ICI时flare或IRAE常见,但多数可管理且无需停用ICI。
  • 基线免疫抑制治疗与较差的无进展生存期相关。

研究设计与样本

  • 2017年1月至2018年1月通过法国3个肿瘤与自身免疫专家网络开展的回顾性队列研究。
  • 纳入112例接受ICI治疗的合并自身免疫病的成人癌症患者,中位随访8个月。

主要发现

  • 最常见的自身免疫病为银屑病(n=31)、类风湿关节炎(n=20)和炎症性肠病(n=14)。
  • 24例(22%)在ICI启动时正在接受免疫抑制治疗。
  • 79例(71%)出现自身免疫病flare和/或其他IRAE,其中53例(47%)flare,47例(42%)其他IRAE。
  • 48例(43%)需要免疫抑制治疗,24例(21%)永久停用ICI。
  • 基线免疫抑制治疗者中位无进展生存期较短(3.8个月 vs 12个月,P=0.006),多因素分析证实。

关键数值与推荐

  • 自身免疫病flare和/或其他IRAE发生于79例(71%)。
  • flare of preexisting autoimmune disease occurred in 53例(47%),其他IRAE in 47例(42%)。
  • 需要免疫抑制治疗48例(43%),永久停用ICI 24例(21%)。
  • 基线免疫抑制治疗者中位无进展生存期3.8个月 vs 12个月(P=0.006)。

临床怎么用

  • 合并自身免疫病的癌症患者使用ICI时,flare或IRAE虽常见但多数可管理,不应常规排除此类患者。
  • 基线免疫抑制治疗可能与较差结局相关,启动ICI前需权衡免疫抑制治疗的必要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Immune checkpoint inhibitors (ICIs) for cancer therapy frequently induce immune-related adverse effects (IRAEs). Therefore, most patients with preexisting autoimmune diseases have been excluded from clinical trials of ICIs. This study was undertaken to evaluate the safety and efficacy of ICIs in patients with preexisting autoimmune disease and cancer. METHODS: A retrospective cohort study was conducted from January 2017 to January 2018 via 3 French national networks of experts in oncology and autoimmunity. Adults with preexisting autoimmune disease who were receiving ICIs were assessed for the occurrence of flare of preexisting autoimmune disease, other IRAEs, and cancer response. RESULTS: The study included 112 patients who were followed up for a median of 8 months. The most frequent preexisting autoimmune diseases were psoriasis (n = 31), rheumatoid arthritis (n = 20), and inflammatory bowel disease (n = 14). Twenty-four patients (22%) were receiving immunosuppressive therapy at ICI initiation. Autoimmune disease flare and/or other IRAE(s) occurred in 79 patients (71%), including flare of preexisting autoimmune disease in 53 patients (47%) and/or other IRAE(s) in 47 patients (42%), with a need for immunosuppressive therapy in 48 patients (43%) and permanent discontinuation of ICI in 24 patients (21%). The median progression-free survival was shorter in patients receiving immunosuppressive therapy at ICI initiation (3.8 months versus 12 months; P = 0.006), confirmed by multivariable analysis. The median progression-free survival was shorter in patients who experienced a flare of preexisting autoimmune disease or other IRAE, with a trend toward better survival in the subgroup without immunosuppressant use or ICI discontinuation. CONCLUSION: Our findings indicate that flares or IRAEs occur frequently but are mostly manageable without ICI discontinuation in patients with a preexisting autoimmune disease. Immunosuppressive therapy at baseline is associated with poorer outcomes.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Tison A, Quéré G, Misery L, et al. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. Arthritis Rheumatol. 2019. PMID: 31379105. doi:10.1002/art.41068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。